Key clinical point: Sotrovimab significantly reduced the risk for complications, hospitalization, or mortality in patients with mild-to-moderate COVID-19.
Major finding: 1% of patients in the sotrovimab group vs 7% in the placebo group experienced disease progression leading to hospitalization (relative risk reduction, 85%; P = .002). Grade 3/4 adverse events were reported in 2% of patients in the sotrovimab group vs 6% of patients in the placebo group.
Study details: The data come from a prespecified, interim analysis of the ongoing, double-blind, placebo-controlled phase 3 COMET-ICE trial assessing the efficacy and safety of sotrovimab in patients with high-risk, ambulatory, mild-to-moderate COVID-19.
Disclosures: The COMET-ICE trial was funded by Vir Biotechnology and GlaxoSmithKline. The COMET-ICE Investigators reported relationships with Vir Biotechnology and GlaxoSmithKline.
Source: Gupta A et al. N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMoa2107934 .